Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL extends hemophilia drug agreement with Bayer
Under the contract extension, Bayer will continue to supply Helixate FS to CSL Behring through 2017. At the same time, the companies settled outstanding litigation relating to the
Under the contract extension, Bayer will continue to supply Helixate FS to CSL Behring through 2017. At the same time, the companies settled outstanding litigation relating to the
The Bioral product for which the application was filed is an enchocleated version of amphotericin B (CAMB), an antifungicidal agent. Amphotericin B is used for treating infections such
The company now anticipates that agency will complete its review and issue its opinion regarding approval within the next 90 days. Genasense is a novel targeted therapy that
Arixtra, an injectable drug, is now indicated for patients with unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) and ST-segment elevation myocardial infarction (STEMI). UA/NSTEMI and STEMI
CT-322 is a proprietary Adnectin protein therapeutic that specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result,
The data extend positive results from a previous preclinical study in which treatment with the compound HE3286, initiated at disease onset, significantly reduced the illness. In that previous
The trial also evaluated the effectiveness of Oracea for maintenance therapy in the treatment of rosacea. Rosacea is characterized by the appearance of inflammatory lesions, skin redness and
Mitsubishi Pharma, owned by Mitsubishi Chemical Holdings, will hold the majority shares of the new business owning 56.4% of the new company. Japanese pharmaceutical companies are increasingly entering
The finding adds new understanding about the causes of childhood brain cancers, according to senior author David Gutmann, co-director of the neuro-oncology program at the Siteman Cancer Center.
“Through this combination, Numira will be better positioned to deliver more complete solutions and a broader range of leading-edge imaging products for the drug discovery research market,” said